Telix Pharmaceuticals Limited today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results